PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTafenoquine
Tafenoquine
Arakoda, Krintafel (tafenoquine) is a small molecule pharmaceutical. Tafenoquine was first approved as Krintafel on 2018-07-20. It is used to treat malaria in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
Arakoda, Krintafel
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tafenoquine succinate
Tradename
Company
Number
Date
Products
ARAKODA60 Degrees PharmaceuticalsN-210607 RX2018-08-08
1 products, RLD, RS
KRINTAFELGSKN-210795 RX2018-07-20
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
arakodaNew Drug Application2025-01-10
kodatefunapproved drug for use in drug shortage2025-02-10
krintafelNew Drug Application2023-08-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
malariaEFO_0001068D008288B54
Agency Specific
FDA
EMA
Expiration
Code
TAFENOQUINE SUCCINATE, KRINTAFEL, GLAXOSMITHKLINE
2025-07-20ODE-201
Patent Expiration
Patent
Expires
Flag
FDA Information
Tafenoquine Succinate, Arakoda, 60 Degrees Pharms
103427912035-12-02U-2582
108885582035-12-02U-2582
117448282035-12-02U-2582
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01B: Antimalarials
— P01BA: Aminoquinoline antimalarials
— P01BA07: Tafenoquine
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
BabesiosisD001404EFO_0007162B60.0—1——12
Covid-19D000086382—U07.1—1———1
Healthy volunteers/patients————1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTafenoquine
INNtafenoquine
Description
N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine is an aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group. It is a member of (trifluoromethyl)benzenes, an aminoquinoline, an aromatic ether, a primary amino compound and a secondary amino compound.
Classification
Small molecule
Drug classAntimalarial
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1
Identifiers
PDB—
CAS-ID106635-80-7
RxCUI—
ChEMBL IDCHEMBL298470
ChEBI ID—
PubChem CID115358
DrugBankDB06608
UNII ID262P8GS9L9 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,430 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
58 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use